Prospective Multicenter Randomized Openlabel Study to Evaluate the Benefit on Renal Function at 12months Post-transplantation of Immunosuppressive Treatment With Withdrawal of Calcineurin Inhibitor at 3months and Combining Mycophenolate Sodium-Everolimus Versus Tacrolimus-Everolimus, in Patients With de Novo Kidney Transplant

Trial Profile

Prospective Multicenter Randomized Openlabel Study to Evaluate the Benefit on Renal Function at 12months Post-transplantation of Immunosuppressive Treatment With Withdrawal of Calcineurin Inhibitor at 3months and Combining Mycophenolate Sodium-Everolimus Versus Tacrolimus-Everolimus, in Patients With de Novo Kidney Transplant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Everolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 24 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 14 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top